@article{ATM21384,
author = {Robert N. Jorissen and Anuratha Sakthianandeswaren and Oliver M. Sieber},
title = {Immunoscore—has it scored for colon cancer precision medicine?},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {For patients with early-stage resectable colon cancer, the principal method for determining prognosis is based on histopathological characterization of the tumor, including the depth of tumor penetration (T stage) and spread to nearby lymph nodes (N stage), with the American Joint Committee on Cancer (AJCC) staging system perhaps the most widely used risk classification system. Other tumor risk parameters considered in clinical practice include grade of differentiation, lymphovascular and perinuclear invasion, microsatellite instability (MSI) status, inadequately sampled lymph nodes, and obstruction or perforation of the bowel at presentation (1).},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21384}
}